Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Paul Wolfe

Pediatrics Marion, IN Medical Doctor

NPI 1669410411 CMS profile 211456

2620 S Western Ave, Marion, IN 46953

Open in the dashboard

General payments

$6,567

342 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Paul Wolfe of Marion, IN is reported in the CMS Open Payments database as having received $6,567 across 342 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $948 37
2024 General $1,308 68
2023 General $1,137 60
2022 General $1,126 69
2021 General $1,064 48
2020 General $700 44
2019 General $285 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Wolfe
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Paul Wolfe were reported at $948. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Paul Wolfe Pediatrics median Middle half National median
2019 $285 $86 $31–$183 $163
2020 $700 $49 $22–$110 $114
2021 $1,064 $68 $27–$158 $132
2022 $1,126 $77 $30–$173 $149
2023 $1,137 $88 $33–$190 $160
2024 $1,308 $94 $34–$206 $164
2025 $948 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $1,842 61 payments
  2. Corium, Inc. $1,342 94 payments
  3. Supernus Pharmaceuticals, Inc. $1,004 65 payments
  4. Tris Pharma Inc $536 17 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $271 21 payments
  6. Sanofi Pasteur Inc. $248 12 payments
  7. Ironshore Pharmaceuticals Inc. $159 8 payments
  8. Adlon Therapeutics L.P. $158 15 payments
  9. Neurelis, Inc. $135 3 payments
  10. Pfizer Inc. $124 7 payments
  11. Other $748 39 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,567 342 payments
Products named General payments · program years 2019–2025
  1. BEXSERO $1,612 58 payments
  2. Azstarys $1,342 94 payments
  3. QELBREE Psychology $694 52 payments
  4. PEDIARIX $559 40 payments
  5. Dyanavel XR Adhd $351 7 payments
  6. Qelbree Viloxazine Hydrochloride $310 13 payments
  7. VYVANSE $303 23 payments
  8. ADHANSIA XR $158 15 payments
  9. VAXELIS $139 6 payments
  10. Dyanavel XR Adhd $137 6 payments
  11. Other $2,208 109 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

342 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record